Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

被引：0
|
作者：
Huihui Li
Fengli Hu
Yanli Zhang
Kai Li
机构：
[1] Heze Municipal Hospital,Department of Neurology
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Disease-modifying therapy; Relapsing–remitting multiple sclerosis; Systematic review; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3489 / 3498
页数：9
相关论文
共 50 条
  • [31] Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
    Parekh, Krupa
    Watkins, Claire
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) : 1265 - 1266
  • [32] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [33] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [34] The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
    Branger, Pierre
    Parienti, Jean-Jacques
    Sormani, Maria Pia
    Defer, Gilles
    PLOS ONE, 2016, 11 (03):
  • [35] Relative Differences in Brain Volume Loss With Teriflunomide Versus Other Disease-Modifying Therapies in Relapsing Multiple Sclerosis: a Systematic Review and Network Meta-Analysis
    Ainsworth, C.
    Higuchi, K.
    Simou, E.
    Guyot, P.
    Greene, N.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 58 - 59
  • [36] Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis
    Xu, Xinghua
    Chi, Sumin
    Wang, Qun
    Li, Chengxin
    Xu, Bainan
    Zhang, Jun
    Chen, Xiaolei
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 25 : 322 - 328
  • [37] Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
    Barzegar, Mahdi
    Houshi, Shakiba
    Sadeghi, Erfan
    Hashemi, Mozhgan Sadat
    Pishgahi, Ghasem
    Bagherieh, Sara
    Afshari-Safavi, Alireza
    Mirmosayyeb, Omid
    Shaygannejad, Vahid
    Zabeti, Aram
    MULTIPLE SCLEROSIS INTERNATIONAL, 2022, 2022
  • [38] Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
    Zhang, Yinan
    Gonzalez Caldito, Natalia
    Shirani, Afsaneh
    Salter, Amber
    Cutter, Gary
    Culpepper, William, II
    Wallin, Mitchell
    Kosa, Peter
    Bielekova, Bibiana
    Lublin, Fred
    Stuve, Olaf
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [39] Disease-modifying therapy in relapsing-remitting multiple sclerosis: efficacy is paramount
    Cristiano, E
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 3 - 7
  • [40] Disease-modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta-analysis
    Valizadeh, Amir
    Fattahi, Mohammad Reza
    Sadeghi, Maryam
    Torbati, Mehrnush Saghab
    Sahraian, Mohammad Ali
    Azimi, Amir Reza
    CNS NEUROSCIENCE & THERAPEUTICS, 2022, 28 (05) : 648 - 657
12345